Cellular Localization of Enzymatically Active Thrombin in Intact Human Tissues by Hirudin Binding

Summary

Cellular sites of coagulation activation within complex, intact tissues have been studied by immunohistochemical techniques. Hirudin, a specific and high affinity inihibitor of the active site of thrombin, together with antibody to hirudin were applied to sections of AMeX-fixed specimens of normal lung, kidney, placenta, freshly incised skin and unperturbed skin obtained at fresh autopsy; to rheumatoid synovial tissue; and to malignant tissue from a variety of tumor types. Staining for thrombin was observed selectively on pulmonary alveolar, rheumatoid synovial, and placental macrophages that express an intact extrinsic coagulation pathway. Staining was also observed restricted to the endothelium of capillaries in freshly incised skin but not in either unperturbed skin or in aged incisions. Staining of tumor cell bodies was observed in small cell carcinoma of the lung, renal cell carcinoma, and malignant melanoma tissues that we found previously to show tumor cell-associated procoagulant activity. This staining occurred commonly on cells within the tumor mass that were distant from stromal fibrinogen/fibrin. By contrast, tumor-associated macrophage but not tumor cell staining was seen in adenocarcinoma and squamous cell carcinoma of the lung, and little or no staining was seen in colon cancer tissue. Negative controls in which either the hirudin probe or its antibody were omitted failed to show staining. These results are in accord with previous findings and suggest that such techniques may be useful for studying the cellular sites of thrombin generation in intact tissues. We postulate that administration of potent and specific thrombin antagonists, such as hirudin, to patients with relevant tumor types might be followed by homing of hirudin to tumor cells in vivo so that effects of local thrombin generation on malignant progression can be determined.

• References

• 1 Zacharski LR, Wojtukiewicz MZ, Costantini V, Omstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Haemost 1992; 18: 104-116
• 2 Zacharski LR, Brown FE, Memoli VA, Rousseau SM. Pathways of coagulation activation in rheumatoid synovium. Clin Immunol Immunopathol 1992; 63: 155-162
• 3 Procyk R, Kudryk B, Callender S, Blombäck B. Accessibility of epitopes on fibrin clots and fibrinogen gels. Blood 1991; 77: 1469-1475
• 4 Zacharski LR, Dunwiddie C, Nutt EM, Hunt J, Memoli VA. Cellular localization of activated factor X by a Xa-specific probe. Thromb Haemost 1991; 65: 545-548
• 5 Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudin. Thromb Haemost 1990; 64: 344-348
• 6 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-229
• 7 Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining Am J Pathol 1986; 125: 431-435
• 8 Schlaeppi J-M. Preparation of monoclonal antibodies to the thrombin/hiru- din complex. Thrombos Rev 1991; 62: 459-470
• 9 Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69: 406-414
• 10 van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JM M, Buller HR, Serruys PW. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88: 2058-2066
• 11 Zoldhelyi P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesbro JH. Recombinant hirudin in patients with chronic stable coronary artery disease. Safety, half-life, and effect on coagulation parameters Circulation 1993; 88: 2015-2022
• 12 Markwardt F. The comeback of hirudin as an antithrombotic agent. Sem Thromb Haemost 1991; 17: 79-81
• 13 Zacharski LR, Meehan KR. Growth Regulatory Mechanisms in Cancer Therapy. In: Fibrinolysis in Disease. Glas-Greenwalt P. ed CRC Press; Boca Raton, FL: 1995. (in press)
• 14 Zacharski LR, Donati MB, Rickies FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 1993; 70: 357-360
• 15 Lebeau B, Chastang C, Brechot J-M, Capron F, Dautzenberg B, Delaise-ments C, Momet M, Brun J, Hurdebourcq J-P, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45
• 16 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
• 17 Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. QancerRes 1991; 51: 4549-4556
• 18 Loeb L, Fleisher MS. Intravenous injections of various substances in animal cancer. JAMA 1913; 60: 1857-1858